Mealey's (April 14, 2021, 4:21 PM EDT) -- SAN FRANCISCO — A Ninth Circuit U.S. Court of Appeals panel on March 24 denied a motion filed by a drug maker and certain of its current and former executive officers requesting that the panel or the Ninth Circuit en banc rehear an appeal of a federal district court’s ruling dismissing several claims for failure to sufficiently plead loss causation in a securities fraud class action lawsuit, ruling that none of the panel’s judges voted in favor of rehearing....